ICER Unsatisfied With Fibrogen’s Roxadustat Evidence; FDA Calls Advisory Committee
ICER held a meeting on February 11th, during which its independent appraisal committee agreed that it was not possible to [...]
NIH Statement on Improving Equity; Francis Collins Announces UNITE Initiative to Address Structural Racism in Biomedical Science
Dr. John Denny, CEO of the NIH’s All of Us Research Program, released a statement on how the NIH is [...]
Sanofi Publishes 2021 Report on Principles in Prescription Drug Pricing, Notes $890 Million in Patient Assistance Programs
Unjustified price increases continue to be a point of contention in the pharma industry. Sanofi has published a report aimed [...]
Novartis and NHS England Agree on Price of Costly SMA Drug; Zolgensma Nearly £1.8 Million per Dose
SMA (spinal muscular atrophy) is characterized by muscle weakness, paralysis, and eventual loss of movement. It is associated with extremely [...]
MSL Society Offers Wednesday Webinar on Navigating KOL Engagements During COVID-19
The Medical Science Liaison Society (MSLS) will host a webinar this Wednesday from 12 PM – 1 PM CST on [...]
ICER Reveals Prescription Drug Cost Sharing Policies, Concludes Many Will Dislike Findings
A recent ICER whitepaper discusses a range of policies designed to limit drug prices. It focuses on three main topics [...]
GOP Avoids Drug Cost Questions During Becerra HHS Hearings
Xavier Becerra is Biden’s pick for HHS (Health and Human Services). Earlier this week, he took questions from Republican lawmakers, [...]
Aetion’s Take on RWE Expansion in Europe
Aetion’s Ashley Jaska, Vice President of Science, and Nicholas Deltour, Vice President of Real-World Solutions, offered their insight into how [...]
Storage a Major Challenge in Genomics Tools for Precision Medicine
Genomics tools are driving progress in precision medicine. These tools, such as next generation sequencing (NGS) technologies, allow for large [...]
Prescription Drugs Only One Piece of High Healthcare Costs–Look to Provider Cost
Dr. Anupam Jena, an associate professor of healthcare policy at Harvard Medical School and doctor at Massachusetts General Hospital, shares [...]
California and New York Newest States Seeking to Create Their Own Contracts With Medicaid
A growing number of states have decided to form their own contracts with Medicaid. Most recently, California and New York [...]
ISMPP Releases Results of Poll on Marketing Scenario
The ISMPP recently published the results of a poll asking respondents how they might respond to a scenario where a [...]
2021 Healthcare Predictions As Democrats Hold House, Senate, Presidential Office
Now that Democrats hold control of the House of Representatives, the Senate, and Biden has been elected president, healthcare is [...]
Register Today for Virtual ISPOR 2021 Conference on HEOR, HTAs, and RWD
ISPOR will host its yearly conference on HEOR (health economics and outcomes research) virtually, from May 17-20. The theme of [...]
A Conversation with Gilead Leader on Impact of RWE in Drug Development
Dr. Diana Brainard, Senior Vice President and Virology Therapeutic Area Head at Gilead Sciences, provides her thoughts on the role [...]
Understanding the Spectrum of Low-Value Care and Economic Implications
In a recent study, researchers compared over one thousand low-value care recommendations from five US healthcare organizations (USPSTF, ACP, ACC/AHA, [...]
The Case for Prescription Drug Price Transparency: Listen to Patients and Providers
Although recent regulations require healthcare systems to provide pricing information, there is no standardized method to do so. With these [...]
The US FDA Has a Different Rubric for Cancer Drug Approval Than the UK and Canada
Different regulatory bodies have different criteria when it comes to drug approval, especially in the case of cancer drugs. The [...]
Sarepta’s New Treatment for Duchenne Muscular Dystrophy Approved by FDA, $1 Million Yearly Cost Despite Lack of Confirmation Studies
Sarepta Therapeutics has created a third drug for use in Duchenne Muscular Dystrophy (DMD), termed Amondys 45. It recently received [...]
How Will Emphasis on Patient Centricity and ICER Influence Payer Decisions?
The 21st Century Cures Act, as well as FDA guidelines, are putting a spotlight on patient centricity—from drug development to [...]
Swedish Scientist Faces Backlash Over COVID-19 Research, Sweden to Strengthen Academic Freedom Laws
Jonas Ludvigsson, a professor of clinical epidemiology at the Karolinska Institute and a pediatrician at Örebro University Hospital, examined the [...]
Pricing Experts Offer Insight Into Use of Advanced Analytics, Note 85% of Companies Lack Sufficient Data or Detailed Pricing Information
85% of interviewed companies lack sufficient data, price quality, or price transparency information to be able to properly apply advanced [...]
2021 Global Medical Affairs Outsourcing Market Research Report Details 2028 Outlook
HealthCare Intelligence has released a report analyzing worldwide trends relating to healthcare outsourcing markets using primary and secondary methods along [...]
New Bills Propose High Taxes for Unjustified Drug Price Increases
Legislators in Washington and Hawaii have introduced bills aimed at drug price increases by pharmaceutical companies. Should these bills be [...]
Aetna Return to ACA Exchanges Reflects Industry-Wide Trend Amid COVID-19 Relief Package Boost
The Aetna insurance division of the CVS Health Corp. will return to the ACA (Affordable Care Act) exchanges in 2022. [...]